A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma

Head and Neck

Volumn 24, Issue 7, 2002, Pages 661-669

  Villaret, Doug ^a   Glisson, Bonnie ^b   Kenady, Daniel ^c   Hanna, Ehab ^d   Carey, Mary ^e   Gleich, Lyon ^f   Yoo, George H ^g   Futran, Neal ^h   Hung, Mien Chie ^b   Anklesaria, Pervin ^e   Heald, Alison E ^e  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e Targeted Genetics Corporation   (United States)

^f UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^g WAYNE STATE UNIVERSITY   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adenovirus E1A gene; E1A Lipid Complex; Gene transfer; Head and neck cancer; Liposome

Indexed keywords

3BETA [N',N' (DIMETHYLAMINOETHANE)CARBAMOYL]CHOLESTEROL; ANTINEOPLASTIC AGENT; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DRUG CARRIER; E1A LIPID COMPLEX; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTHENIA; BLEEDING; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEX FORMATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; E1A GENE; FACE EDEMA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GENE; HANGOVER; HEAD AND NECK CARCINOMA; HUMAN; MALE; METABOLIC DISORDER; MULTICENTER STUDY; MYALGIA; NEUROLOGIC DISEASE; NONVIRAL GENE THERAPY; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; RESPIRATORY TRACT DISEASE; SQUAMOUS CELL CARCINOMA;

ADENOVIRUS E1A PROTEINS; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHOLESTEROL; DRUG CARRIERS; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRALESIONAL; LIPOSOMES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0036303883     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.10107     Document Type: Article

References (31)

1. Cancer statistics, 2000
2. Head and neck cancer
3. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer
4. Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene
5. Disruption of epithelial cell-matrix interactions induces apoptosis
6. Adenovirus E1A represses protease gene expression and inhibits metastasis of human tumor cells
7. Repression of a matrix metalloprotease gene by E1A correlates with its ability to bind to cell type-specific transcription factor AP-2
8. E1a induces the expression of epithelial characteristics
9. Adenovirus E1A-mediated tumor suppression by a c-erbB-2/neu-independent mechanism
10. Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo
11. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A
12. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway
13. Inhibition of nuclear factor-kappaB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis
14. A novel cationic liposome reagent for efficient transfection of mammalian cells
15. Effect of cationic cholesterol derivatives on gene transfer and protein kinase C activity
16. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans
17. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu
18. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head-neck cancer
19. Phase I E1A gene therapy in patients with advanced breast and ovarian cancers
20. Clinical experience with HLA-B7 plasmid DNA/lipid complex (Allovectin7) in advanced squamous cell carcinoma of the head and neck (SCCHN)
21. Three phase II trials of intratumoral injection with a replication-deficient adenovirus carrying the p53 gene (AD5CMV-P53) in patients with recurrent/refractory head and neck cancer
22. A prospective phase II trial of ONYX.015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience)
23. A controlled trial of intratumoral ONYX-015, a selectively- replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
24. Anti-edipdermal growth factor receptor antibody cetuximab (C225) in combination with radiation therapy in patients with advanced head and neck cancer
25. Oncogenes and cellular sensitivity to radiotherapy. A study on murine keratinocytes transformed by v-H-ras, v-myc, v-neu, adenovirus E1a and mutant p53
26. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
27. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene
28. Adenovirus lacking the 19-kDa and 55-kDa E1B genes exerts a marked cytotoxic effect in human malignant cells
29. E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of IkappaB kinases and nuclear factor kappaB activities
30. Targeting of lipid-protamine-DNA (LPD) complexes using DSPE-PEG5000-LHRH or DSPE-PEG5000-RGD